Novel purification technologies for industrial biotherapeutic manufacture

用于工业生物治疗制造的新型纯化技术

• 批准号: 101793
• 金额: $ 27.3万
• 依托单位: PURIDIFY LTD.
• 依托单位国家: 英国
• 项目类别: Collaborative R&D
• 财政年份: 2014
• 资助国家: 英国
• 起止时间: 2014 至 无数据
• 项目状态: 已结题
• 来源: https://gtr.ukri.org/projects?ref=101793
• 关键词: Novel; purification; technologies; industrial; biotherapeutic

Global demand for cheaper biotherapeutics, which represent many of the new tools in the fight against diseases such as cancer, drives the need for a reduction in manufacturing costs. A significant proportion of current costs arise from the purification technologies currently used to ensure the safety and efficacy of these treatments. Improvements to these technologies are fundamentally limited with the existing dominant technology reaching a point where it is unable to match performance increases in the rest of the manufacturing process. This will impact the ability for drug manufacturers to reach economies of scale and meet market demands from patients. Puridify’s novel nanofibre purification technology has the potential to revolutionise the industrial scale production of biotherapeutics. The material’s properties can overcome current manufacturing limitations by increasing productivity 10-fold, potentially reducing biotherapeutic manufacturing costs by up to 25%. This will play an important role in widening patient access to expensive drugs in both the UK and worldwide. Puridify seeks to develop key drivers for adoption under a CRD project.

全球对更便宜的生物治疗药物的需求推动了降低制造成本的需求，生物治疗药物是对抗癌症等疾病的许多新工具。当前成本的很大一部分来自当前用于确保这些治疗的安全性和有效性的纯化技术。这些技术的改进从根本上受到限制，因为现有的主导技术已达到无法与制造过程其余部分的性能提高相匹配的程度。这将影响药品制造商实现规模经济和满足患者市场需求的能力。 Puridify 的新型纳米纤维纯化技术有可能彻底改变生物治疗药物的工业规模生产。该材料的特性可以将生产率提高 10 倍，从而克服当前的制造限制，从而可能将生物治疗的制造成本降低高达 25%。这将在扩大英国和全球患者获得昂贵药物的机会方面发挥重要作用。 Puridify 致力于开发 CRD 项目下采用的关键驱动因素。